Holen Sie sich die Stockscreener-App
31.32
3.39%
0.965
Schlusskurs vom Vortag:
$30.35
Offen:
$30.48
24-Stunden-Volumen:
662.16K
Relative Volume:
0.69
Marktkapitalisierung:
$2.48B
Einnahmen:
$399.58M
Nettoeinkommen (Verlust:
$-54.04M
KGV:
-41.75
EPS:
-0.75
Netto-Cashflow:
$40.13M
1W Leistung:
-0.92%
1M Leistung:
+8.39%
6M Leistung:
-12.66%
1J Leistung:
+54.20%
1-Tages-Spanne:
$30.45
$31.59
1-Wochen-Bereich:
$29.30
$31.89
52-Wochen-Spanne:
$19.73
$47.32
Veracyte Inc Stock (VCYT) Company Profile
Firmenname
Veracyte Inc
Sektor
Branche
Telefon
(650) 243-6300
Adresse
6000 SHORELINE COURT, SUITE 300, SOUTH SAN FRANCISCO, CA
Vergleichen Sie VCYT mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
VCYT
Veracyte Inc
|
31.35 | 2.48B | 399.58M | -54.04M | 40.13M | -0.75 |
|
TMO
Thermo Fisher Scientific Inc
|
422.40 | 159.05B | 42.90B | 6.52B | 6.72B | 17.05 |
|
DHR
Danaher Corp
|
197.50 | 140.21B | 23.82B | 3.77B | 4.90B | 5.15 |
|
IDXX
Idexx Laboratories Inc
|
476.31 | 35.17B | 3.90B | 887.87M | 798.08M | 10.67 |
|
A
Agilent Technologies Inc
|
108.56 | 30.47B | 6.53B | 1.26B | 1.31B | 4.35 |
|
IQV
Iqvia Holdings Inc
|
152.65 | 26.47B | 15.41B | 1.37B | 2.11B | 7.50 |
Veracyte Inc Stock (VCYT) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-03-20 | Eingeleitet | Craig Hallum | Buy |
| 2024-12-05 | Herabstufung | Goldman | Buy → Neutral |
| 2024-11-15 | Eingeleitet | Wolfe Research | Outperform |
| 2024-10-16 | Eingeleitet | UBS | Buy |
| 2024-10-10 | Eingeleitet | Guggenheim | Buy |
| 2024-02-23 | Bestätigt | Needham | Buy |
| 2023-01-18 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2023-01-05 | Eingeleitet | Scotiabank | Sector Outperform |
| 2022-01-07 | Eingeleitet | Stephens | Overweight |
| 2021-11-18 | Fortgesetzt | Goldman | Buy |
| 2021-06-15 | Eingeleitet | Raymond James | Outperform |
| 2021-02-18 | Fortgesetzt | Needham | Buy |
| 2021-01-28 | Eingeleitet | Truist | Buy |
| 2020-11-10 | Eingeleitet | KeyBanc Capital Markets | Sector Weight |
| 2020-09-09 | Eingeleitet | Morgan Stanley | Underweight |
| 2019-07-31 | Eingeleitet | Lake Street | Buy |
| 2019-07-02 | Eingeleitet | Needham | Buy |
| 2018-11-29 | Herabstufung | Janney | Buy → Neutral |
| 2018-10-31 | Hochstufung | Janney | Neutral → Buy |
| 2017-11-07 | Herabstufung | Janney | Buy → Neutral |
| 2017-11-07 | Herabstufung | Piper Jaffray | Overweight → Neutral |
| 2017-08-31 | Fortgesetzt | BTIG Research | Buy |
| 2016-11-14 | Fortgesetzt | Leerink Partners | Outperform |
| 2015-12-18 | Eingeleitet | Cantor Fitzgerald | Buy |
| 2015-06-11 | Bestätigt | Leerink Partners | Outperform |
| 2013-11-26 | Eingeleitet | William Blair | Outperform |
Alle ansehen
Veracyte Inc Aktie (VCYT) Neueste Nachrichten
Breaking Down the Benefits of Clinical Trial Participation in Cancer Care - Curetoday
Veracyte Announces Expanded Availability of Decipher Prostate Test to Patients with Metastatic Prostate Cancer - BioSpace
Veracyte launches prostate metastatic test - MSN
Crafting an Individual Treatment Plan for Patients With Prostate Cancer - Curetoday
Cathie Wood's Ark Invest Loads Up On Intellia Therapeutics, Offloads Meta Platforms - Benzinga
Veracyte launches metastatic prostate cancer test - Investing.com
Veracyte launches metastatic prostate cancer test By Investing.com - Investing.com South Africa
Veracyte launches prostate metastatic test (VCYT:NASDAQ) - Seeking Alpha
Veracyte (VCYT) Boosts Cancer Care with New Genomic Classifier L - GuruFocus
Veracyte Announces Expanded Availability of Decipher Prostate Te - GuruFocus
Veracyte Announces Expanded Availability Of Decipher Prostate Test To Patients With Metastatic Prostate Cancer - marketscreener.com
Veracyte Announces Expanded Availability of Decipher Prostate Test to Patients with Metastatic Prostate Cancer | VCYT Stock News - GuruFocus
Press Release Distribution & PR Platform - ACCESS Newswire
Veracyte Announces Multiple Abstracts Demonstrating Power of Dec - GuruFocus
Breakthrough Cancer Insights: 18 New Studies Confirm Veracyte Decipher Test's Power in Prostate and Bladder Cancer - Stock Titan
Veracyte Announces Decipher Prostate Genomic Classifier Results are Linked to Real-World Data in National Cancer Institute’s SEER Specialized Database Release - 01net
Veracyte data joins NCI SEER database for research By Investing.com - Investing.com South Africa
Veracyte Announces Decipher Prostate Genomic Classifier Results - GuruFocus
Veracyte data joins NCI SEER database for research - Investing.com
Veracyte Announces Decipher Prostate Genomic Classifier Results are Linked to Real-World Data in National Cancer Institute's SEER Specialized Database Release | VCYT Stock News - GuruFocus
Should You Continue to Hold Veracyte Stock in Your Portfolio? - MSN
Veracyte to Release First Quarter 2025 Financial Results on May 7, 2025 - 01net
Veracyte to Release First Quarter 2025 Financial Results on May 7, 2025 | VCYT Stock News - GuruFocus
Cancer Diagnostics Leader Veracyte Announces Q1 2025 Earnings Date: Key Updates Coming May 7 - Stock Titan
Why Veracyte (VCYT) is a Top Momentum Stock for the Long-Term - Yahoo Finance
Here's Why Veracyte (VCYT) is a Strong Growth Stock - Yahoo Finance
Veracyte And 2 More Stocks That Might Be Trading Below Their Estimated Value - Yahoo Finance
Here's How Much You'd Have If You Invested $1000 in Veracyte a Decade Ago - MSN
Veracyte (VCYT) Just Overtook the 20-Day Moving Average - Yahoo Finance
Strength Seen in Veracyte (VCYT): Can Its 13.0% Jump Turn into More Strength? - Nasdaq
Guggenheim cuts Veracyte stock price target to $37, keeps Buy rating By Investing.com - Investing.com South Africa
Guggenheim cuts Veracyte stock price target to $37, keeps Buy rating - Investing.com Australia
Minimal Residual Disease Testing Market Forecast Report, 2025-2030 - GlobeNewswire Inc.
Veracyte Scores Relative Strength Rating Upgrade; Hits Key Threshold - MSN
Veracyte (VCYT) Introduces AI-Powered Cancer Detection – Faster and More Accurate Than Ever! - Insider Monkey
9 AI News and Ratings on Investors’ Radar - Insider Monkey
Craig-Hallum bullish on Veracyte, initiates with a Buy - MSN
Veracyte (VCYT) Up 0.7% Since Last Earnings Report: Can It Continue? - Yahoo Finance
Wall Street Analysts Believe Veracyte (VCYT) Could Rally 35.05%: Here's is How to Trade - Yahoo
New Data Demonstrate Accuracy of Veracyte’s Whole-Genome Sequencing-Based MRD Testing Platform for Muscle-Invasive Bladder Cancer - 01net
Veracyte Cancer Diagnostic Platform Shows Higher Specificity Than Blood Tests - MarketScreener
Finanzdaten der Veracyte Inc-Aktie (VCYT)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.16%
0.03%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):